Matches in SemOpenAlex for { <https://semopenalex.org/work/W1608023012> ?p ?o ?g. }
- W1608023012 endingPage "2376" @default.
- W1608023012 startingPage "2369" @default.
- W1608023012 abstract "SummaryBackground: Terutroban is a selective prostaglandin endoperoxide (TP) receptor antagonist with antithrombotic, antivasoconstrictive and antiatherosclerotic properties and is currently in development for long‐term cardiovascular secondary prevention. Objectives: TAIPAD is an international, double‐blind, randomized controlled study comparing the effects of five dosages of oral terutroban vs. aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients. Patients/methods: After 10 day’s placebo run‐in, included patients (n = 435; ankle‐brachial pressure index, 0.7 ± 0.1) were randomly allocated to aspirin 75 mg day−1, terutroban 1, 2.5, 5, 10 or 30 mg day−1 or placebo. On day 5, the placebo group was reallocated to one of the terutroban groups for the rest of the study (day 83). Ex vivo platelet aggregation induced by the thromboxane analog U46619 (7 μm) was measured 24 h after dosing, as well as platelet aggregation induced by arachidonic acid (AA), collagen and ADP. Results: Terutroban dose‐dependently inhibited U46619‐induced platelet aggregation at days 5 and 83. At day 5, the inhibition was significant vs. placebo for all terutroban dosages (P<0.001). Terutroban (5, 10 and 30 mg day−1) was at least as effective as aspirin in inhibiting platelet aggregation induced by arachidonic acid (AA), collagen and adenosine diphosphate (ADP). Terutroban was well tolerated, with a safety profile similar to aspirin. Conclusions: In PAD patients, terutroban dose‐dependently inhibited platelet aggregation 24 h after dosing, and was at least as effective as aspirin at 5, 10 and 30 mg day−1. Terutroban was well tolerated. Background: Terutroban is a selective prostaglandin endoperoxide (TP) receptor antagonist with antithrombotic, antivasoconstrictive and antiatherosclerotic properties and is currently in development for long‐term cardiovascular secondary prevention. Objectives: TAIPAD is an international, double‐blind, randomized controlled study comparing the effects of five dosages of oral terutroban vs. aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients. Patients/methods: After 10 day’s placebo run‐in, included patients (n = 435; ankle‐brachial pressure index, 0.7 ± 0.1) were randomly allocated to aspirin 75 mg day−1, terutroban 1, 2.5, 5, 10 or 30 mg day−1 or placebo. On day 5, the placebo group was reallocated to one of the terutroban groups for the rest of the study (day 83). Ex vivo platelet aggregation induced by the thromboxane analog U46619 (7 μm) was measured 24 h after dosing, as well as platelet aggregation induced by arachidonic acid (AA), collagen and ADP. Results: Terutroban dose‐dependently inhibited U46619‐induced platelet aggregation at days 5 and 83. At day 5, the inhibition was significant vs. placebo for all terutroban dosages (P<0.001). Terutroban (5, 10 and 30 mg day−1) was at least as effective as aspirin in inhibiting platelet aggregation induced by arachidonic acid (AA), collagen and adenosine diphosphate (ADP). Terutroban was well tolerated, with a safety profile similar to aspirin. Conclusions: In PAD patients, terutroban dose‐dependently inhibited platelet aggregation 24 h after dosing, and was at least as effective as aspirin at 5, 10 and 30 mg day−1. Terutroban was well tolerated." @default.
- W1608023012 created "2016-06-24" @default.
- W1608023012 creator A5032937627 @default.
- W1608023012 creator A5047736375 @default.
- W1608023012 creator A5055517858 @default.
- W1608023012 creator A5060873298 @default.
- W1608023012 creator A5067642836 @default.
- W1608023012 creator A5069836649 @default.
- W1608023012 creator A5074067891 @default.
- W1608023012 creator A5090828404 @default.
- W1608023012 date "2010-11-01" @default.
- W1608023012 modified "2023-09-29" @default.
- W1608023012 title "Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study" @default.
- W1608023012 cites W1963805121 @default.
- W1608023012 cites W1969016210 @default.
- W1608023012 cites W1980727193 @default.
- W1608023012 cites W1997531859 @default.
- W1608023012 cites W2004409526 @default.
- W1608023012 cites W2024352468 @default.
- W1608023012 cites W2054262691 @default.
- W1608023012 cites W2065113747 @default.
- W1608023012 cites W2077200797 @default.
- W1608023012 cites W2078349288 @default.
- W1608023012 cites W2079929867 @default.
- W1608023012 cites W2084572764 @default.
- W1608023012 cites W2085308671 @default.
- W1608023012 cites W2098430424 @default.
- W1608023012 cites W2107932438 @default.
- W1608023012 cites W2124939010 @default.
- W1608023012 cites W2129746956 @default.
- W1608023012 cites W2134308892 @default.
- W1608023012 cites W2160810790 @default.
- W1608023012 cites W2170100458 @default.
- W1608023012 cites W2887712073 @default.
- W1608023012 cites W311320695 @default.
- W1608023012 cites W4231194744 @default.
- W1608023012 cites W4296154158 @default.
- W1608023012 doi "https://doi.org/10.1111/j.1538-7836.2010.04020.x" @default.
- W1608023012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20723034" @default.
- W1608023012 hasPublicationYear "2010" @default.
- W1608023012 type Work @default.
- W1608023012 sameAs 1608023012 @default.
- W1608023012 citedByCount "26" @default.
- W1608023012 countsByYear W16080230122012 @default.
- W1608023012 countsByYear W16080230122013 @default.
- W1608023012 countsByYear W16080230122014 @default.
- W1608023012 countsByYear W16080230122015 @default.
- W1608023012 countsByYear W16080230122016 @default.
- W1608023012 countsByYear W16080230122018 @default.
- W1608023012 countsByYear W16080230122019 @default.
- W1608023012 countsByYear W16080230122021 @default.
- W1608023012 countsByYear W16080230122023 @default.
- W1608023012 crossrefType "journal-article" @default.
- W1608023012 hasAuthorship W1608023012A5032937627 @default.
- W1608023012 hasAuthorship W1608023012A5047736375 @default.
- W1608023012 hasAuthorship W1608023012A5055517858 @default.
- W1608023012 hasAuthorship W1608023012A5060873298 @default.
- W1608023012 hasAuthorship W1608023012A5067642836 @default.
- W1608023012 hasAuthorship W1608023012A5069836649 @default.
- W1608023012 hasAuthorship W1608023012A5074067891 @default.
- W1608023012 hasAuthorship W1608023012A5090828404 @default.
- W1608023012 hasBestOaLocation W16080230121 @default.
- W1608023012 hasConcept C126322002 @default.
- W1608023012 hasConcept C142724271 @default.
- W1608023012 hasConcept C162156334 @default.
- W1608023012 hasConcept C181199279 @default.
- W1608023012 hasConcept C185592680 @default.
- W1608023012 hasConcept C202751555 @default.
- W1608023012 hasConcept C204787440 @default.
- W1608023012 hasConcept C26291073 @default.
- W1608023012 hasConcept C27081682 @default.
- W1608023012 hasConcept C2776785769 @default.
- W1608023012 hasConcept C2777628954 @default.
- W1608023012 hasConcept C2778078955 @default.
- W1608023012 hasConcept C2781024287 @default.
- W1608023012 hasConcept C2781080829 @default.
- W1608023012 hasConcept C2909112448 @default.
- W1608023012 hasConcept C3018697912 @default.
- W1608023012 hasConcept C55493867 @default.
- W1608023012 hasConcept C71924100 @default.
- W1608023012 hasConcept C89560881 @default.
- W1608023012 hasConcept C98274493 @default.
- W1608023012 hasConceptScore W1608023012C126322002 @default.
- W1608023012 hasConceptScore W1608023012C142724271 @default.
- W1608023012 hasConceptScore W1608023012C162156334 @default.
- W1608023012 hasConceptScore W1608023012C181199279 @default.
- W1608023012 hasConceptScore W1608023012C185592680 @default.
- W1608023012 hasConceptScore W1608023012C202751555 @default.
- W1608023012 hasConceptScore W1608023012C204787440 @default.
- W1608023012 hasConceptScore W1608023012C26291073 @default.
- W1608023012 hasConceptScore W1608023012C27081682 @default.
- W1608023012 hasConceptScore W1608023012C2776785769 @default.
- W1608023012 hasConceptScore W1608023012C2777628954 @default.
- W1608023012 hasConceptScore W1608023012C2778078955 @default.
- W1608023012 hasConceptScore W1608023012C2781024287 @default.
- W1608023012 hasConceptScore W1608023012C2781080829 @default.
- W1608023012 hasConceptScore W1608023012C2909112448 @default.
- W1608023012 hasConceptScore W1608023012C3018697912 @default.